A PHASE 1/2, MULTICENTER, OPEN LABEL, DOSE ESCALATION & DOSE EXPANSION STUDY OF JK06, A 5T4 ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER

Registry ID

JK06.1.01

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

SALUBRIS BIOTHERAPEUTICS, INC.

Start date

2026-05-07

Last update

2025-09-25

Conditions

• METASTATIC CANCERS

Related clinical trials

• A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 TRIAL OF DOMVANALIMAB, ZIMBERELIMAB, AND CHEMOTHERAPY VERSUS NIVOLUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, AND ESOPHAGEAL ADENOCARCINOMA
• IN VIVO LUNG PERFUSION (IVLP) AS AN ADJUVANT TREATMENT FOR PATIENTS WITH RESECTABLE OR UNRESECTABLE PULMONARY METASTASES OF COLORECTAL CARCINOMAS
• A PHASE 1/2A TWO-PART, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF OC-001 AS MONOTHERAPY AND IN COMBINATION WITH AN ANTI-PD-L1 ANTIBODY IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS
• PHASE 1 STUDY OF ZW49 IN PATIENTS WITH LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC HER2-EXPRESSING CANCERS
• PHASE 1 TRIAL OF ZW25 IN PATIENTS WITH LOCALLY ADVANCED (UNRESECTABLE) AND/OR METASTATIC HER2-EXPRESSING CANCERS

View on source registry